Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Macrobid · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg |
| 2 | ACTIVE_COMPARATOR | Macrobid® Capsules 100 mg |
| Name | Type | Description |
|---|---|---|
| Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg | DRUG | 100mg, single dose fed |
| Macrobid® Capsules 100 mg | DRUG | 100mg, single dose fed |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female 1. Women of childbearing potential must have negative serum Beta-human chorionic gonadotropin (HCG) pregnancy tests performed within 14 days prior to of the study and on the evening prior to e...
Macrobid is a small molecule drug being developed by Viatris Inc. for use in healthy volunteers. It is currently in Phase 1 clinical development, with two completed trials studying its effects in healthy individuals.
Macrobid is developed by Viatris Inc., a company traded on the stock exchange under the ticker VTRS. The drug is currently in Phase 1 clinical development.
Macrobid is in Phase 1 clinical development. It has completed two Phase 1 trials, and there are no active trials currently ongoing.
Macrobid has two completed Phase 1 clinical trials: NCT00649285, a food study of Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg and Macrobid Capsules 100 mg, and NCT01018342, a fed study of Mylan Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg and Macrobid Capsules 100 mg. Both trials enrolled healthy volunteers in the United States.
Macrobid is a brand name for nitrofurantoin monohydrate/macrocrystals capsules. The clinical trials for Macrobid compare it to generic versions of nitrofurantoin monohydrate/macrocrystals capsules, indicating they are the same active ingredient.